Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus: a pilot trial
| العنوان: | Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus: a pilot trial |
|---|---|
| المؤلفون: | Hiroyasu Bando, Fumiaki Obata, Harutaka Yamaguchi, Kenji Tani, Issei Imoto, Ryo Tabata |
| المصدر: | The Journal of Medical Investigation. 64:50-57 |
| بيانات النشر: | University of Tokushima Faculty of Medicine, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Adult, Blood Glucose, Male, medicine.medical_specialty, Every other day, Pilot Projects, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, Drug Administration Schedule, General Biochemistry, Genetics and Molecular Biology, Group B, 03 medical and health sciences, Hba1c level, 0302 clinical medicine, Glucosides, Japan, Sodium-Glucose Transporter 2, Internal medicine, Empagliflozin, Humans, Hypoglycemic Agents, Medicine, In patient, Prospective Studies, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors, Glycemic, Glycated Hemoglobin, business.industry, Pilot trial, Type 2 Diabetes Mellitus, General Medicine, Middle Aged, Treatment Outcome, Endocrinology, Diabetes Mellitus, Type 2, Female, business |
| الوصف: | The terminal elimination half-life (t1/2) of empagliflozin is 13.1 hours. Accordingly, we hypothesized that the administration of empagliflozin every other day might improve glycemic control in patients with type 2 diabetes mellitus, not being inferior to the therapy every day. We investigated the clinical effects and safety of the addition of empagliflozin every day or every other day to type 2 diabetic patients with a poor control in glycemia. Thirteen Japanese patients diagnosed as type 2 diabetes mellitus recruited to this study. Subjects were divided into two groups; one was treatment with 10 mg of empagliflozin every day (Group A), the other was 10 mg of empagliflozin every other day (Group B). The comparable study of multiple clinical indexes between the 2 groups was made before and 8, 16, and 24 weeks after the treatment. After the treatment for 24 weeks, the HbA1c level was decreased both in group A (from 7.5%±1.1% to 6.5%±0.8%) and in group B (from 7.6%±0.8% to 7.2%±0.5%). This pilot trial suggested the possibility of 10-mg every other day administration with empagliflozin for Japanese patients with type 2 diabetes mellitus. J. Med. Invest. 64: 50-57, February, 2017. |
| تدمد: | 1349-6867 1343-1420 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3c376af3160a72e0864ef566f5537a6 https://doi.org/10.2152/jmi.64.50 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....a3c376af3160a72e0864ef566f5537a6 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13496867 13431420 |
|---|